(secondQuint)Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC).

 This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in NSCLC patients with unresectable IIIA and dry IIIB disease.

 The endpoint will be to determine MTD of the combination.

.

 Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)@highlight

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

